<?xml version="1.0" encoding="UTF-8"?>
<p>Awareness of cardiovascular toxicity associated with proteasome inhibitors is increasing (Koulaouzidis &amp; Lyon, 
 <xref rid="bjh15394-bib-0025" ref-type="ref">2017</xref>). Integrated nonclinical and clinical risk assessment has previously reported no clinically meaningful effects of ixazomib on QTc or heart rate (Gupta 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0017" ref-type="ref">2015b</xref>). The incidence of cardiovascular AEs in patients with no pre‐existing cardiac risk factors was limited in the present study and included 2 patients (3%) with atrial fibrillation reported as a treatment‐emergent SAE. Twelve patients (19%) reported AEs within the cardiac disorders system organ class; however, these patients all had pre‐existing cardiac risk factors. Cardiovascular AEs, including heart failure (Roussel 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0044" ref-type="ref">2016</xref>), have previously been reported with KRd in NDMM patients. Cardiovascular toxicities have also been reported with bortezomib‐Rd in NDMM patients, including: treatment‐related cardiac arrhythmia (5%) and general cardiac events (21%) (Durie 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0012" ref-type="ref">2017</xref>), and QTc interval (6%); and atrial fibrillation (2%) (Richardson 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0041" ref-type="ref">2010</xref>). The prescribing information for both carfilzomib (
 <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202714s015lbl.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202714s015lbl.pdf</ext-link>) and bortezomib (
 <ext-link ext-link-type="uri" xlink:href="http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf</ext-link>) notes cardiac toxicities under warnings and precautions reflective of these safety concerns, but this is not noted in the ixazomib prescribing information (
 <ext-link ext-link-type="uri" xlink:href="https://www.ninlaro.com/prescribing-information.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ninlaro.com/prescribing-information.pdf</ext-link>; 
 <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf</ext-link>) and our data support no such safety concerns with ixazomib‐based combinations.
</p>
